Vanda Pharmaceuticals Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Public

  • Employees
  • 533

Employees

  • Stock Symbol
  • VNDA

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $3.44
  • (As of Friday Closing)

Vanda Pharmaceuticals General Information

Description

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 2200 Pennsylvania Avenue Northwest
  • Suite 300E
  • Washington, DC 20037
  • United States
+1 (202)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Corporate Office
  • 2200 Pennsylvania Avenue Northwest
  • Suite 300E
  • Washington, DC 20037
  • United States
+1 (202)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vanda Pharmaceuticals Stock Performance

As of 20-Nov-2026, Vanda Pharmaceuticals’s stock price is $3.44. Its current market cap is $208M with 60.5M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.44 $3.67 $3.42 - $9.94 $208M 60.5M 1.05M -$4.62

Vanda Pharmaceuticals Financials Summary

As of 30-Sep-2026, Vanda Pharmaceuticals has a trailing 12-month revenue of $229M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 149,675 238,395 (89,025) (237,227)
Revenue 229,278 216,105 198,772 192,640
EBITDA (157,235) (126,730) (13,122) 10,673
Net Income (274,829) (220,474) (18,900) 2,509
Total Assets 382,327 488,948 656,204 648,440
Total Debt 21,971 12,622 12,360 9,404
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vanda Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vanda Pharmaceuticals‘s full profile, request access.

Request a free trial

Vanda Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Vanda Pharmaceuticals‘s full profile, request access.

Request a free trial

Vanda Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies t
Drug Discovery
Washington, DC
533 As of 2025

Basel, Switzerland
 

Mumbai, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vanda Pharmaceuticals Competitors (45)

One of Vanda Pharmaceuticals’s 45 competitors is Novartis, a Corporation company based in Basel, Switzerland.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novartis Corporation Basel, Switzerland
Cipla Corporation Mumbai, India
Evonile Pharma Private Equity-Backed Mumbai, India
Sanofi Corporation Gentilly, France
Merck & Co. Corporation Rahway, NJ
You’re viewing 5 of 45 competitors. Get the full list »

Vanda Pharmaceuticals Patents

Vanda Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026174219-A1 Method of treatment of hypertension with iloperidone Pending 13-Feb-2025
WO-2026156184-A1 Method of treatment with milsaperidone Pending 17-Jan-2025
WO-2026152024-A1 Method of treating nausea and vomiting after glp-1r agonist administration Pending 09-Jan-2025
US-20250375409-A1 Treatment of rem behavior disorder Pending 11-Jun-2024
AU-2025224045-A1 Treatment of dry eye disease Pending 22-Feb-2024 A61K31/53
To view Vanda Pharmaceuticals’s complete patent history, request access »

Vanda Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vanda Pharmaceuticals Investments (2)

Vanda Pharmaceuticals’s most recent deal was a Corporate Asset Purchase with AnaptysBio (Rights to Imsidolimab). The deal was made on 26-Feb-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
AnaptysBio (Rights to Imsidolimab) 26-Feb-2026 Corporate Asset Purchase Buildings and Property
Actelion Pharmaceuticals (United States and Canadian Rights to Ponvory) 07-Dec-2023 Corporate Asset Purchase Buildings and Property
To view Vanda Pharmaceuticals’s complete investments history, request access »

Vanda Pharmaceuticals ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

32.3 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Vanda Pharmaceuticals’s complete esg history, request access »

Vanda Pharmaceuticals FAQs

  • When was Vanda Pharmaceuticals founded?

    Vanda Pharmaceuticals was founded in 2002.

  • Where is Vanda Pharmaceuticals headquartered?

    Vanda Pharmaceuticals is headquartered in Washington, DC.

  • What is the size of Vanda Pharmaceuticals?

    Vanda Pharmaceuticals has 533 total employees.

  • What industry is Vanda Pharmaceuticals in?

    Vanda Pharmaceuticals’s primary industry is Drug Discovery.

  • Is Vanda Pharmaceuticals a private or public company?

    Vanda Pharmaceuticals is a Public company.

  • What is Vanda Pharmaceuticals’s stock symbol?

    The ticker symbol for Vanda Pharmaceuticals is VNDA.

  • What is the current stock price of Vanda Pharmaceuticals?

    As of 20-Nov-2026 the stock price of Vanda Pharmaceuticals is $3.44.

  • What is the current market cap of Vanda Pharmaceuticals?

    The current market capitalization of Vanda Pharmaceuticals is $208M.

  • What is Vanda Pharmaceuticals’s current revenue?

    The trailing twelve month revenue for Vanda Pharmaceuticals is $229M.

  • Who are Vanda Pharmaceuticals’s competitors?

    Novartis, Cipla, Evonile Pharma, Sanofi, and Merck & Co. are some of the 45 competitors of Vanda Pharmaceuticals.

  • What is Vanda Pharmaceuticals’s annual earnings per share (EPS)?

    Vanda Pharmaceuticals’s EPS for 12 months was -$4.62.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process